Association of baseline hyperglycemia with outcomes of patients with and without diabetes with acute ischemic stroke treated with intravenous thrombolysis: A propensity score-matched analysis from the SITS-ISTR registry

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3105697 25 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Association of baseline hyperglycemia with outcomes of patients with and without diabetes with acute ischemic stroke treated with intravenous thrombolysis: A propensity score-matched analysis from the SITS-ISTR registry
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Available data from observational studies on the association of admission hyperglycemia (aHG) with outcomes of patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT) are contradictory, especially when stratified by diabetes mellitus (DM) history. We assessed the association of aHG (≥144 mg/dL) with outcomes stratified by DM history using propensity score-matched (PSM) data from the SITS-ISTR. The primary safety outcome was symptomatic intracranial hemorrhage (SICH); 3-month functional independence (FI) (modified Rankin Scale [mRS] scores 0-2) represented the primary efficacy outcome. Patients with and without aHG did not differ in baseline characteristics both in the non-DM (n = 12,318) and DM (n = 6,572) PSM subgroups. In the non-DM group, patients with aHG had lower 3-month FI rates (53.3% vs. 57.9%, P < 0.001), higher 3-month mortality rates (19.2% vs. 16.0%, P < 0.001), and similar symptomatic intracerebral hemorrhage (SICH) rates (1.7% vs. 1.8%, P = 0.563) compared with patients without aHG. Similarly, in the DM group, patients with aHG had lower rates of 3-month favorable functional outcome (mRS scores 0-1, 34.1% vs. 39.3%, P < 0.001) and FI (48.2% vs. 52.5%, P < 0.001), higher 3-month mortality rates (23.7% vs. 19.9%, P < 0.001), and similar SICH rates (2.2% vs. 2.7%, P = 0.224) compared with patients without aHG. In conclusion, aHG was associated with unfavorable 3-month clinical outcomes in patients with and without DM and AIS treated with IVT. © 2019 by the American Diabetes Association.
Έτος δημοσίευσης:
2019
Συγγραφείς:
Tsivgoulis, G.
Katsanos, A.H.
Mavridis, D.
Lambadiari, V.
Roffe, C.
MacLeod, M.J.
Sevcik, P.
Cappellari, M.
Nevšímalová, M.
Toni, D.
Ahmed, N.
Περιοδικό:
Frontiers in Diabetes
Εκδότης:
American Diabetes Association Inc.
Τόμος:
68
Αριθμός / τεύχος:
9
Σελίδες:
1861-1869
Λέξεις-κλειδιά:
aged; Article; blood clot lysis; brain hemorrhage; brain ischemia; clinical outcome; correlational study; diabetes mellitus; diabetic patient; female; functional assessment; human; hyperglycemia; major clinical study; male; mortality rate; priority journal; propensity score; Rankin scale; blood; brain ischemia; cerebrovascular accident; complication; diabetes mellitus; fibrinolytic therapy; glucose blood level; hyperglycemia; middle aged; prognosis; register; treatment outcome; very elderly, fibrinolytic agent; tissue plasminogen activator, Aged; Aged, 80 and over; Blood Glucose; Brain Ischemia; Diabetes Mellitus; Female; Fibrinolytic Agents; Humans; Hyperglycemia; Male; Middle Aged; Prognosis; Propensity Score; Registries; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome
Επίσημο URL (Εκδότης):
DOI:
10.2337/db19-0440
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.